Capstone Holding (CAPS) Stock Price
Capstone Holding Price
Over the last 7 years Capstone Holding grew revenue by 56.9% annually, reaching 46.88 M USD. Earnings per share have declined at 66.6% per year over the last 2 years. For Capstone Holding, the net margin of -45.3% is down versus 5.9% a few years ago. The consensus 12-month price target for Capstone Holding is 6.12 USD, about 133.6% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus.
Capstone Holding stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Capstone Holding business model & stock analysis
Frequently asked questions about Capstone Holding
Capstone Therapeutics Corp operates in the biotechnology industry, focusing on the development of novel therapeutic peptides for the treatment of serious medical conditions. The company's business model revolves around leveraging its expertise in peptide biology and targeting specific disease pathways to develop innovative drug candidates. Through extensive research and clinical trials, Capstone Therapeutics Corp aims to develop highly effective and safe peptide-based treatments. By focusing on this specialized field, the company seeks to bring novel and potentially life-changing therapies to patients in need. Capstone Therapeutics Corp's business model emphasizes scientific expertise, innovation, and the pursuit of breakthrough treatments in the biotechnology sector.
Capstone Therapeutics Corp is primarily active in the biotechnology and pharmaceutical industries.
The main competitors of Capstone Therapeutics Corp in the market include companies such as Amgen Inc., Pfizer Inc., Novartis AG, and Johnson & Johnson.
Capstone Therapeutics Corp is a pharmaceutical company headquartered in Tempe, Arizona. Founded in 1987, Capstone Therapeutics focuses on the development and commercialization of novel therapeutics in the field of biotechnology. The company primarily engages in the research and development of peptide-based drugs for various medical conditions, including metabolic diseases, such as diabetes and obesity. Capstone Therapeutics has a strong commitment to advancing medical science and has been actively involved in several clinical trials and collaborative research programs. With its extensive expertise and dedication to innovation, Capstone Therapeutics Corp continues to make significant contributions to the field of biopharmaceuticals.
Capstone Therapeutics Corp has achieved several significant milestones. One notable achievement includes the completion of Phase 1 clinical trials for their lead product candidate, AZX100. Additionally, the company has successfully secured several important patents and intellectual property rights related to their innovative drug delivery platform technologies. Furthermore, Capstone Therapeutics Corp has also formed strategic collaborations and partnerships with renowned healthcare organizations to further enhance their research and development efforts. These milestones demonstrate the company's commitment to advancing medical innovation and their potential for long-term growth in the biopharmaceutical industry.
Capstone Therapeutics Corp primarily operates in the United States.
Capstone Therapeutics Corp represents values of innovation, integrity, and growth. With a corporate philosophy focused on advanced medical research and development, Capstone is dedicated to creating life-changing therapies for patients worldwide. The company emphasizes a commitment to scientific excellence and collaboration, driving its pursuit of breakthrough treatments in areas such as orphan diseases and regenerative medicine. Capstone Therapeutics Corp believes in the power of cutting-edge technology and strategic partnerships to drive success and deliver value to its stakeholders. Through its visionary approach, Capstone aims to revolutionize healthcare and improve patients' lives globally.
Analysts currently set an average price target of 6.12 USD for the Capstone Holding stock (median: 6.12 USD), implying +118.6 % versus the latest price. The consensus is based on 7 analyst ratings.
7 analysts currently rate the Capstone Holding stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Capstone Holding to generate revenue of 72.11 M USD and earnings per share of 0.04 USD.
Converted at the current exchange rate, the Capstone Holding share trades at 2.35 EUR (2.62 USD).
Capstone Therapeutics Corp is a biotechnology company focused on developing therapies for the treatment of diseases. They have three main business areas: therapeutic development, diagnostic development, and intellectual property licensing. The development of therapeutics is Capstone's largest business area. They are working on several therapy projects, including AZX100 and CTP-656. AZX100 is an experimental drug for the treatment of fibrosis, currently being investigated in clinical Phase IIa. CTP-656 is a therapeutic for the treatment of cystic fibrosis and uses a novel formulation of Ivacaftor, an already approved drug for cystic fibrosis treatment. Capstone has also developed a promising diagnostic platform based on the identification of protein biomarkers. These can be used for early detection and monitoring of diseases such as Alzheimer's, cancer, and cardiovascular diseases. They are currently working with partners to further develop this platform and create diagnostic tests. Another important business area for Capstone is intellectual property licensing. They hold several patents based on biotechnological discoveries, covering various aspects of medical research and therapy development. They market these patents by selling licenses to other companies and research institutions. Capstone Therapeutics Corp also has partnerships with other companies and research institutions. They collaborate with New York University on the development of therapeutics for cardiovascular diseases and with the University of Alabama on the development of therapeutics against cancer. These partnerships allow the company to expand its research and development capabilities. Capstone's business model is based on the development of therapeutics and diagnostics, intellectual property licensing, and collaboration with other companies and research institutions. Their products and services aim to detect and treat diseases earlier. By developing new therapeutics and diagnostics and commercializing patents, the company aims to increase its revenue and strengthen its position in the biotechnology industry.
The expected revenue of Capstone Holding is 72.11 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Capstone Holding is 10,880.00 USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Capstone Holding is currently 70.42. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Capstone Holding stock.
The price-to-sales ratio (P/S) of Capstone Holding is currently 0.01. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Capstone Holding stock.
The Eulerpool Quality Score for Capstone Holding is 2/10.
The ISIN of Capstone Holding is US14068E2081. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Capstone Holding is A2PRWA. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Capstone Holding is CAPS. The ticker symbol is used to trade Capstone Holding shares on the stock exchange.
Capstone Holding stock
Capstone Holding Peer Group
Capstone Holding Ticker
Capstone Holding FIGI
All fundamentals and in-depth analysis of Capstone Holding
Our stock analysis for Capstone Holding stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Capstone Holding. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.